文献速递消化系统肿瘤

基于血液ctDNA的多模态检测方法检测结直肠癌具有高准确性

High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer.
PubMed 文献 · Ann Oncol · 2023-10-05

研究在623份血液样本中评估一种整合基因组学、表观基因组学、片段组学及蛋白质组学的多模态ctDNA血液检测方法。该检测方法检测结直肠癌的敏感度为93%、特异度为90%,按TNM分期I期敏感度为84%、II期为94%、III期为96%(P<0.024)。

要点

  • 多模态ctDNA血液检测结直肠癌敏感度93%、特异度90%(623份血液样本)。
  • 按TNM分期敏感度:I期84%、II期94%、III期96%(70/73)(P<0.024)。
  • 精炼版检测晚期癌前病变的敏感度为23%。

核心结论

  • 基于血液的多模态ctDNA检测方法检测结直肠癌具有高准确性。
  • 这种微创、可及且便捷的检测方法可能有助于提高结直肠癌筛查的有效性。

研究设计与样本

  • 研究在两种队列的血液样本中测试一种新型多模态ctDNA血液检测方法,该法整合基因组学、表观基因组学、片段组学,精炼版还整合蛋白质组学。
  • 队列一为来自结直肠癌巴塞罗那粪便筛查项目的连续粪便免疫化学试验(FIT)阳性个体。
  • 队列二为确诊结直肠癌的患者。
  • 主要终点为检测方法在不同TNM分期检测结直肠癌的性能。
  • 次要终点为检测方法检测晚期癌前病变(晚期腺瘤或晚期锯齿状病变)的能力。

主要发现

  • 检测方法检测结直肠癌的敏感度为93%,特异度为90%。
  • 按TNM分期的结直肠癌检测敏感度:I期为84%,II期为94%,III期为96%(70/73)(P<0.024)。
  • 精炼版检测方法(包括蛋白质和更新生物信息学阈值)检测晚期癌前病变的敏感度为23%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Detection of circulating tumor DNA (ctDNA) is a minimally invasive and convenient blood-based screening strategy that may increase effectiveness of colorectal cancer (CRC) screening. PATIENTS AND METHODS: A novel multimodal ctDNA-based blood assay that integrates genomics, epigenomics and fragmentomics, as well as proteomics in a refined version, was tested in blood samples from two cohorts: (i) consecutive fecal immunochemical test (FIT)-positive individuals from the CRC Barcelona stool-based screening program; (ii) patients diagnosed with CRC. Primary endpoint was the performance of the test to detect CRC at different tumor-node-metastasis (TNM) stages. Secondary endpoint was the ability of the test to detect advanced precancerous lesions (advanced adenoma or advanced serrated lesion). RESULTS: A total of 623 blood samples were analyzed in the primary analysis. Sensitivity and specificity of the assay to detect CRC was 93% and 90%, respectively. The sensitivity of CRC detection according to TNM stages was 84% for stage I, 94% for stage II and 96% for stage III (70/73) (P< 0.024). Sensitivity to detect advanced precancerous lesions was 23% with a refined version of the test (including protein and updating bioinformatic thresholding). CONCLUSION: A blood-based multimodal ctDNA assay detected CRC with high accuracy. This minimally invasive, accessible and convenient assay may help to increase the effectiveness of CRC screening.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bessa X, Vidal J, Balboa JC, et al. High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer. Ann Oncol. 2023. PMID: 37805131. doi:10.1016/j.annonc.2023.09.3113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。